Japan Tissue Engineering Co.,Ltd. [7774.T]
TOKYO, May 01 (Pulse News Wire) – Japan Tissue Engineering CO.,LTD. (7774.T) reported its fiscal year 2026 fourth quarter results, highlighting a revenue of ¥50 million.
Despite facing challenges such as reduced case numbers and the absence of milestone income from Teijin, the company expects to achieve profitability in fiscal year 2027 driven by key products like Jack OA and Jasmine. For the fiscal year ending March 31, 2026, the company recorded a revenue of ¥50 million, marking a significant shift towards profitability. Operating profit was negative due to ongoing investments but showed signs of improvement compared to the previous year. lower net profit stood at -¥734 million, reflecting strategic expenses and investment losses.
Looking ahead, Japan Tissue Engineering outlined several growth strategies for fiscal year 2027. Key initiatives include expanding the market reach of Jack OA and Jasmine, enhancing contract manufacturing services, and advancing global expansion through new product launches and partnerships. The company projects robust sales growth across its segments, aiming for sustained black ink. In addition, the firm emphasized the importance of cost control and operational efficiency to meet its ambitious targets.
With a solid cash position and strong pipeline development, Japan Tissue Engineering remains confident in achieving its financial goals and driving long-term value for shareholders.
🟢 Confidence: High AI-translated content.